Krystal Biotech Inc (KRYS)
165.00
+5.53
(+3.47%)
USD |
NASDAQ |
May 15, 14:16
Krystal Biotech Cash from Financing (TTM): 211.86M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 211.86M |
December 31, 2023 | 202.75M |
September 30, 2023 | 203.20M |
June 30, 2023 | 191.93M |
March 31, 2023 | 37.36M |
December 31, 2022 | 35.35M |
September 30, 2022 | 234.35M |
June 30, 2022 | 233.74M |
March 31, 2022 | 202.84M |
December 31, 2021 | 347.68M |
September 30, 2021 | 145.75M |
June 30, 2021 | 144.41M |
March 31, 2021 | 262.08M |
Date | Value |
---|---|
December 31, 2020 | 118.02M |
September 30, 2020 | 118.18M |
June 30, 2020 | 131.18M |
March 31, 2020 | 107.73M |
December 31, 2019 | 107.52M |
September 30, 2019 | 171.51M |
June 30, 2019 | 167.90M |
March 31, 2019 | 73.88M |
December 31, 2018 | 73.85M |
September 30, 2018 | 8.866M |
June 30, 2018 | 49.48M |
March 31, 2018 | 51.47M |
December 31, 2017 | 51.77M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
35.35M
Minimum
Dec 2022
347.68M
Maximum
Dec 2021
168.77M
Average
169.70M
Median
Cash from Financing (TTM) Benchmarks
Axsome Therapeutics Inc | 278.26M |
Catalyst Pharmaceuticals Inc | 130.04M |
EyePoint Pharmaceuticals Inc | 192.30M |
Viking Therapeutics Inc | 873.23M |
Edgewise Therapeutics Inc | 294.22M |